Matthew R Reynolds1, J Scott Allison2, Andrea Natale3, Ian L Weisberg4, Kenneth A Ellenbogen5, Mark Richards6, Wen-Hua Hsieh7, Julie Sutherland7, Christopher P Cannon8. 1. Lahey Hospital & Medical Center, Burlington, Massachusetts; Baim Institute for Clinical Research, Boston, Massachusetts. Electronic address: matthew.reynolds@baiminstitute.org. 2. Heart Center Research, Huntsville, Alabama. 3. Texas Cardiac Arrhythmia Research Foundation, Austin, Texas. 4. Baptist Heart and Vascular Institute, Pensacola, Florida. 5. Virginia Commonwealth University, Richmond, Virginia. 6. ProMedica Toledo Hospital, Toledo, Ohio. 7. Baim Institute for Clinical Research, Boston, Massachusetts. 8. Baim Institute for Clinical Research, Boston, Massachusetts; Brigham & Women's Hospital, Boston, Massachusetts.
Abstract
OBJECTIVES: This study sought to determine whether uninterrupted apixaban would have similar rates of bleeding and thromboembolic events as does minimally interrupted apixaban at the time of atrial fibrillation (AF) ablation and to compare those results with rates in historical patients treated with uninterrupted warfarin. BACKGROUND: The safety, efficacy, and optimal dosing regimen for apixaban at the time of AF ablation are uncertain. METHODS: This prospective, multicenter clinical trial enrolled 306 patients undergoing catheter ablation for nonvalvular AF and randomized 300 touninterrupted versus minimally interrupted (holding 1 dose) periprocedural apixaban. A retrospective cohort of patients treated with uninterrupted warfarin at the same centers was matched to the apixaban-treated subjects for comparison. Endpoints included clinically significant bleeding, major bleeding, and nonhemorrhagic stroke or systemic embolism (SE) from the time of ablation through 30 days. RESULTS: There were no stroke or SE events. Clinically significant bleeding occurred in 11.3% of 150 evaluable patients on uninterrupted apixaban and 9.7% of 145 evaluable patients on interrupted apixaban (risk difference: 1.7% [95% confidence interval: -5.5% to 8.8%]; p = NS). Rates of major bleeding were 1.3% with uninterrupted apixaban, and 2.1% with interrupted (risk difference: -0.7%; p = NS). The rates of clinically significant and major bleeding were similar for all apixaban patients combined (10.5% and 1.7%), compared with the matched warfarin group (9.8% and 1.4%). CONCLUSIONS: Both uninterrupted and minimally interrupted apixaban at the time of AF ablation were associated with a very low rate of thromboembolic events, and rates of both major (<2%) and clinically significant bleeding were similar to uninterrupted warfarin. (Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation [AEIOU]; NCT02608099).
RCT Entities:
OBJECTIVES: This study sought to determine whether uninterrupted apixaban would have similar rates of bleeding and thromboembolic events as does minimally interrupted apixaban at the time of atrial fibrillation (AF) ablation and to compare those results with rates in historical patients treated with uninterrupted warfarin. BACKGROUND: The safety, efficacy, and optimal dosing regimen for apixaban at the time of AF ablation are uncertain. METHODS: This prospective, multicenter clinical trial enrolled 306 patients undergoing catheter ablation for nonvalvular AF and randomized 300 to uninterrupted versus minimally interrupted (holding 1 dose) periprocedural apixaban. A retrospective cohort of patients treated with uninterrupted warfarin at the same centers was matched to the apixaban-treated subjects for comparison. Endpoints included clinically significant bleeding, major bleeding, and nonhemorrhagic stroke or systemic embolism (SE) from the time of ablation through 30 days. RESULTS: There were no stroke or SE events. Clinically significant bleeding occurred in 11.3% of 150 evaluable patients on uninterrupted apixaban and 9.7% of 145 evaluable patients on interrupted apixaban (risk difference: 1.7% [95% confidence interval: -5.5% to 8.8%]; p = NS). Rates of major bleeding were 1.3% with uninterrupted apixaban, and 2.1% with interrupted (risk difference: -0.7%; p = NS). The rates of clinically significant and major bleeding were similar for all apixabanpatients combined (10.5% and 1.7%), compared with the matched warfarin group (9.8% and 1.4%). CONCLUSIONS: Both uninterrupted and minimally interrupted apixaban at the time of AF ablation were associated with a very low rate of thromboembolic events, and rates of both major (<2%) and clinically significant bleeding were similar to uninterrupted warfarin. (Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation [AEIOU]; NCT02608099).
Authors: Rhanderson Cardoso; Stephan Willems; Edward P Gerstenfeld; Atul Verma; Richard Schilling; Stefan H Hohnloser; Ken Okumura; Matias Nordaby; Marc A Brouwer; Hugh Calkins Journal: Clin Cardiol Date: 2018-12-07 Impact factor: 2.882
Authors: Ghada A Bawazeer; Hadeel A Alkofide; Aya A Alsharafi; Nada O Babakr; Arwa M Altorkistani; Tarek S Kashour; Michael Miligkos; Khalid M AlFaleh; Lubna A Al-Ansary Journal: Cochrane Database Syst Rev Date: 2021-10-21
Authors: Francesco De Sensi; Gennaro Miracapillo; Luigi Addonisio; Marco Breschi; Alberto Cresti; Pasquale Baratta; Francesco Paneni; Ugo Limbruno Journal: Medicina (Kaunas) Date: 2019-08-20 Impact factor: 2.430
Authors: Indranill Basu-Ray; Dibbendhu Khanra; Péter Kupó; Jared Bunch; Sue A Theus; Anindya Mukherjee; Sumit K Shah; András Komócsi; Adedayo Adeboye; John Jefferies Journal: J Arrhythm Date: 2021-01-29